Former MSD head of R&D Roger Perlmutter has continued the swift development track for cancer start-up Eikon Therapeutics, filing an IPO to build its already healthy cash position further. Eikon has ...
Google launched a Gemini command-line tool last year, and now it has a new AI-centric command-line option for cloud products.
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Eikon Therapeutics increased the ...
Despite progress made in cancer immunotherapy, some patients don’t respond to these treatments or they stop responding after a period of time. Eikon Therapeutics’ lead drug candidate could address ...
Eikon Therapeutics raised an upsized US$381m late Wednesday from its Nasdaq IPO that included participation by Merck, a banker involved in the offering told IFR. The banks were multiple times ...
MILLBRAE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. ("Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing important, innovative medicines to ...
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Eikon Therapeutics, a star-studded biotechnology ...
Oncology-focused Eikon Therapeutics Inc. set the terms of its IPO Jan. 28, selling 17.648 million shares at a price range between $16 to $18 per share. At the top of the range, the Millbrae, ...
Cancer-focused Eikon Therapeutics is seeking $273.5 million in its bid to trade on the Nasdaq, while hair growth specialist Veradermics is looking for $181.1 million in its foray onto the New York ...
Eikon Therapeutics (EIKN), a cancer drug developer led by Merck (MRK) veteran Roger Perlmutter, has filed for its U.S. IPO seeking a valuation of up to $908M with roughly 17.6M shares on offer. The ...
Eikon Therapeutics, former MSD head of R&D Roger Perlmutter's new project, is hoping to raise up to $318 million from a Nasdaq listing, in another signal of building confidence in the biopharma sector ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results